DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR PREMARIN
Clinical Trials for Premarin
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00000175 | The Effects of Sex Hormones on Cognition and Mood in Older Adults | Terminated | National Institute on Aging (NIA) | N/A | This study is investigating the effects of hormone replacement therapy on memory, mental abilities and mood in older adults aged 65-90. During the nine month long study, men will take testosterone for three months and women will take estrogen for three months. At four points during the study (once every three months), participants will complete a test battery and have blood drawn. |
| NCT00000555 | Women's Angiographic Vitamin and Estrogen Trial (WAVE) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | To assess whether hormonal replacement therapy and/or antioxidant treatment would stabilize or inhibit progression, and induce regression of coronary plaques. The mechanisms by which these treatments modified atherosclerosis in women were also explored. |
| NCT00002976 | Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer | Terminated | Eastern Cooperative Oncology Group | Phase 3 | RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer. |
| NCT00002976 | Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer | Terminated | National Cancer Institute (NCI) | Phase 3 | RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer. |
| NCT00002976 | Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer | Terminated | Southwest Oncology Group | Phase 3 | RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer. |
| NCT00002976 | Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer | Terminated | Gynecologic Oncology Group | Phase 3 | RATIONALE: Estrogen replacement therapy may improve quality-of-life in postmenopausal women with endometrial cancer. It is not yet known whether estrogen replacement therapy will affect cancer recurrence. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of estrogen replacement therapy in treating women who have stage I or stage II endometrial cancer. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Premarin
Condition Name
Condition MeSH
Clinical Trial Locations for Premarin
Trials by Country
Clinical Trial Progress for Premarin
Clinical Trial Phase
Clinical Trial Sponsors for Premarin
Sponsor Name
